Treatment of Castration-naive Metastatic Prostate Cancer

Zineb Hamilou; Giulia Baciarello; Karim Fizazi

doi:10.1016/j.euf.2018.02.004

Treatment of Castration-naive Metastatic Prostate Cancer

Eur Urol Focus. 2017 Dec;3(6):518-521. doi: 10.1016/j.euf.2018.02.004. Epub 2018 Feb 27.

Authors

Zineb Hamilou¹, Giulia Baciarello², Karim Fizazi³

Affiliations

¹ Institut Gustave Roussy, Département de Médecine Oncologique, Université Paris-Saclay, Villejuif, France; Centre Hospitalier de l'Université de Montréal, Montréal, Canada.
² Institut Gustave Roussy, Département de Médecine Oncologique, Université Paris-Saclay, Villejuif, France.
³ Institut Gustave Roussy, Département de Médecine Oncologique, Université Paris-Saclay, Villejuif, France. Electronic address: Karim.fizazi@gustaveroussy.fr.

PMID: 29500136
DOI: 10.1016/j.euf.2018.02.004

Abstract

Both docetaxel+androgen deprivation therapy (ADT) and abiraterone acetate 1000mg/d+prednisone/prednisolone 5mg/d+ADT improved survival in patients with metastatic castration-naive prostate cancer. Their use should be offered and guided by patient's own characteristics.

Publication types

Review

MeSH terms

Abiraterone Acetate / administration & dosage
Androgen Antagonists / administration & dosage
Antineoplastic Agents, Hormonal / administration & dosage
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Disease-Free Survival
Docetaxel / administration & dosage
Drug Administration Schedule
Humans
Male
Neoplasm Metastasis
Prednisone / administration & dosage
Prostatic Neoplasms, Castration-Resistant / drug therapy*
Prostatic Neoplasms, Castration-Resistant / mortality
Treatment Outcome

Substances

Androgen Antagonists
Antineoplastic Agents, Hormonal
Docetaxel
Abiraterone Acetate
Prednisone